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Introduction 
Peptide growth factors regulate diverse processes from
cell survival and proliferation to migration and 
programmed cell death. Due to their central role in 
growth regulation, growth factors are major players in 
the development and progression of cancer. Among this 
broad class of molecules, those comprising the EGF-
like family are amongst the best characterized. In this
Deep Insight, I will elaborate on the evidence 
implicating one such protein, heparin-binding EGF-like 
growth factor (HB-EGF), in tumor biology and how its
activity may be targeted for therapeutic gain. 
HB-EGF: a member of the EGF-like 
growth factor family 
Heparin-binding EGF-like growth factor (HB-EGF) is a 
member of the epidermal growth factor (EGF)-like 
growth factor family of proteins that bind to and 
activate the EGF receptor (EGFR) and its associated 
receptors ERBB2, ERBB3 and ERBB4. The extended 
family comprises 15 members, all of which conform 
broadly to common structural framework centered 
around 6 cysteine residues in the sequence: CX7CX4-
5CX10-13CXCX8GXRC. Disulphide bond formation 
between 3 pairs of cysteines gives rise to the 
characteristic 3-looped EGF-like motif that mediates 
high-affinity binding to receptors (reviewed in Wilson 
et al., 2009). 
The EGF-like growth factors achieve their effects 
through interaction with one or more ErbB receptor 
tyrosine kinases. The ERBB receptors are class I 
transmembrane proteins that homo- or heterodimerize 
following ligand binding and undergo auto-
phosphorylation on defined tyrosine residues to 
generate recognition motifs for interactors that mediate 
downstream signaling cascades. Among the ERBB 
proteins, ERBB2 is an orphan receptor with no known 
ligand, whereas ERBB3 lacks functional intrinsic 
tyrosine kinase activity. In addition, the EGF-like 
growth factors show specificity in ERBB binding, with 
some factors such as EGF, amphiregulin (AREG) and 
TGFα selective for ERBB1 but others such as HB-EGF 
and betacellulin (BTC) able to interact with ERBB1 
and ERBB4. Consequently, as a result of differential 
intrinsic receptor activity, ligand selectivity and 
modulation of ligand availability by interactions with 
heparin, a wide range of downstream responses can be 
evoked following ligand-ERBB interaction (Citri and 
Yarden, 2006). 
HB-EGF: structure, molecular 
interactions and function 
HB-EGF was originally identified as a secreted product 
of macrophages that was purified on the basis of its 
high affinity for heparin (Higashiyama et al., 1991). 
The gene is encoded on the long arm of chromosome 5, 
at 5q23, and gives rise to a 208 amino acid protein of 
20-22 kDa in size. Determination of the primary 
peptide sequence revealed the presence in HB-EGF of 
an extended N-terminal domain that was absent in the 
prototypical EGFR ligands EGF and transforming 
growth factor-alpha (TGFα). Notably, the N-terminal 
sequence in HB-EGF is enriched in basic amino acids 
that are positively charged at physiological pH and 
enable interaction with negatively charged heparin 
sulphate proteoglycans both on the cell surface and in 
the extracellular matrix. 
HB-EGF is synthesized as a single pass membrane-
anchored precursor with a short cytoplasmic tail 
(Figure 1).  
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Figure 1. Molecular structure of HB-EGF. The figure illustrates in schematic form the secondary structure of HB-EGF. The protein 
possesses a short cytoplasmic region, a single transmembrane domain, and an ectodomain that harbors the 3-looped EGF-like motif 
characteristic of this growth factor family. Vertical arrows indicate primary sites of ectodomain cleavage. Molecules that interact with HB-
EGF are indicated in blue. 
 
Membrane-anchored proHB-EGF undergoes a number 
of post-translational modifications ranging from O-
linked glycosylation of the N-terminal ectodomain, N-
terminal truncations, phosphorylation of the 
cytoplasmic domain and regulated cleavage of the 
entire ectodomain. The significance of these 
modifications will be considered in subsequent 
sections. 
Among the EGFR ligands, proHB-EGF is notable for 
the number of proteins and other molecules with which 
it interacts, including transmembrane receptors, 
adhesion molecules, and transcriptional regulators as 
described below. 
(i) Transmembrane receptors: the best-studied 
functions of HB-EGF are as a ligand for the 
EGFR/ErbB1 and the related receptor ErbB4. High-
affinity interactions with receptors are mediated via the 
3-looped EGF-like motif and result in receptor 
autophosphorylation and initiation of downstream 
signaling cascades. Interestingly, the biological effects 
evoked by HB-EGF binding to ErbB1 and ErbB4 are 
distinct, with the former typically promoting 
proliferation but the latter stimulating chemotaxis and 
migration (Elenius et al., 1997). Interactions between 
the membrane-anchored form of HB-EGF and ErbB 
receptors expressed on adjacent cells also mediate both 
cell survival (Singh et al., 2007) and intercellular 
adhesion functions (Raab et al., 1996; Paria et al., 
1999). More recently, radioligand binding assays with 
125I-labeled HB-EGF using the breast cancer cell line 
MDA-MB 453 revealed the existence of a novel 
receptor that was subsequently identified as the 
metalloendopeptidase N-arginine dibasic convertase 
(NRDc). In that study, NRDc was found to enhance 
HB-EGF stimulated migration of tumor cells in an 
EGFR/Erb1-dependent manner (Nishi et al., 2001). 
(ii) Heparan sulphate proteoglycans (HSPGs): HB-EGF 
was purified from the conditioned medium of a 
macrophage-like cell line on the basis of its high 
affinity for heparin (Higashiyama et al., 1991). 
Interaction of HB-EGF with heparin, in the form of 
HSPGs present on cell surfaces and in the extracellular 
matrix is known to enhance ErbB receptor binding 
affinity as well as bioactivity (Paria et al., 1999; 
Higashiyama et al., 1993). 
(iii) CD9 and integrins: CD9 is a member of the 
tetraspanin family of transmembrane proteins that 
interacts with membrane-anchored HB-EGF via its 
heparin-binding domain (Sakuma et al., 1997) and 
upregulates its ability to stimulate juxtacrine activation 
of the EGFR expressed on adjacent cells (Higashiyama 
et al., 1995). HB-EGF and CD9 were also found to be 
co-expressed in gastric cancers (Murayama et al., 
2002), although the prognostic significance of these 
observations has not been determined. CD9 and HB-
EGF were also demonstrated to exist in complex with 
integrin α3β1 at sites of cell-cell junctions (Nakamura 
et al., 1995) where the multiprotein complex 
waspredicted to participate in cell-cell adhesion. 
(iv) Cytoplasmic tail interactors: several binding 
partners for the cytoplasmic domain of proHB-EGF 
were identified using either yeast 2-hybrid or co-
immunoprecipitation strategies, including the 
cochaperone BAG-1 and the transcriptional repressors 
PLZF and Bcl6. Interaction between BAG-1 and 
proHB-EGF was found to augment the prosurvival 
function of proHB-EGF (Lin et al., 2001). Conversely, 
association between the C-terminal fragment of HB-
EGF that is liberated following ectodomain shedding, 
with PLZF or Bcl6 leads to nuclear export or 
degradation, respectively of the transcriptional 
repressors and a resulting inhibition of repressive 
activity (Nanba et al., 2003; Kinugasa et al., 2007; 
Hirata et al., 2009). The relevance of these interac ions 
to cancer will be considered in more detail below. 
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Figure 2. Regulated processing and activity of HB-EGF. ProHB-EGF expressed on the plasma membrane undergoes ectodomain 
cleavage mediated by enzymes of the matrix metalloproteinase (MMP) and a disintegrin and metalloproteinase (ADAM) families (A). 
Release of the mature, soluble protein facilitates both autocrine (B) and paracrine (C) activation of ERBB receptors expressed on the 
same or adjacent cells, respectively. The membrane-anchored proHB-EGF can also activate ERBB receptors via juxtacrine signaling (D). 
In addition to release of the ectodomain, regulated cleavage releases the Cterminal cytoplasmic fragment, HB-EGF-C (E), which can 
translocate to the nucleus to effect either nuclear export (F) or degradation (G), respectively, of the transcriptional repressors PLZF or 
Bcl6. 
 
Regulated processing of proHB-
EGF 
Like all ERBB ligands, HB-EGF is synthesized as a 
membrane-anchored precursor that is trafficked to the 
plasma membrane and subsequently processed to yield 
the mature, soluble growth factors. Regulated 
processing of the HB-EGF precursor represents a 
critical control point in ligand function since it 
represents the conversion from a membrane-anchored, 
non-diffusible state to a diffusible protein that has a 
greatly expanded sphere of influence on surrounding 
cells and tissues (Figure 2). 
In addition to normal post-translational maturation f 
HB-EGF, regulation of precursor processing is highly 
relevant to cancer, since many of the enzymes that 
cleave HB-EGF and other EGFR ligands are 
themselves upregulated in cancer versus normal cells
(Murphy, 2008). The signals and enzymes responsible 
for liberation of the HB-EGF ectodomain will be 
considered in the following sections. 
Several metalloproteinases have been implicated in 
ectodomain shedding of proHB-EGF including matrix 
metalloproteinase-3 (MMP-3) (Suzuki et al., 1997), 
MMP-7 (Yu et al., 2002), ADAM10 (Yan et al., 2002), 
ADAM12 (Asakura et al., 2002) and TNFα-converting 
enzyme (TACE)/ADAM17 (Sahin et al., 2004). In 
forced expression experiments, ADAM9 was 
demonstrated to promote both basal and TPA-
stimulated proHB-EGF processing (Izumi et al., 1998). 
However, subsequent evaluation of ADAM9-/- MEFs 
revealed no differences in processing with wild type 
MEFs (Weskamp et al., 2002) suggesting that there is 
some redundancy among ADAM factors that cleave 
proHB-EGF. Elegant studies using cells from mice 
deficient in specific ADAM family members identified 
ADAM-17/TACE as the primary mediator of HB-EGF 
cleavage (Sahin et al., 2004). Importantly, ADAM-17 
itself is upregulated in a range of tumor types (Tanaka 
et al., 2005) and at least part of its association with 
tumor progression is likely to reflect increased 
processing of EGFR ligands including HB-EGF. 
Ectodomain shedding of HB-EGF has also been 
implicated in EGFR transactivation in tumor cells 
downstream of multiple discrete agonists including G-
protein coupled receptor activators (Filardo et al., 2000; 
Madarame et al., 2003; Schäfer et al., 2004a; Schäfer et 
al., 2004b; Yano et al., 2004; Itoh et al., 2005), Ser/Thr 
kinase activators (Ebi et al., 2010), ligands for gp130 
cytokine receptors (Ogunwobi and Beales, 2008) and 
others. EGFR transactivation by GPCR-dependent HB-
EGF cleavage has been discussed recently (reviewed in 
Higashiyama et al., 2008) and will not be considere 
further here. 
Although much attention has focused on the fate of the 
soluble HB-EGF that is liberated following precursor 
cleavage, the C-terminal fragment of HB-EGF that 
remains following ectodomain shedding has also been 
shown to be functional, independently of proHB-EGF. 
HB-EGF-C, comprising both the transmembrane and 
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cytoplasmic domains, was demonstrated to undergo 
nuclear translocation following cleavage of the HB-
EGF ectodomain (Nanba et al., 2003; Nanba et al., 
2004; Toki et al., 2005). Detection of the C-terminal 
fragment of HB-EGF in nuclei was consistent with an 
earlier report from our group identifying nuclear 
localization of HB-EGF as a feature of aggressive 
disease in bladder cancer (Adam et al., 2003). Nuclear 
localization of HB-EGF-C was accompanied by nuclear 
export of the promyelocytic leukemia zinc finger 
(PLZF) protein, identified as an interactor for HB-EGF-
C by yeast 2-hybrid analysis (Nanba et al., 2003). 
PLZF is a sequence-specific transcriptional repressor 
and inhibitor of cell cycle transit that achieves its effect 
by binding via its zinc finger domains to the promoters 
of target genes such as cyclin A (Yeyati et al., 1999). 
Export from the nucleus therefore prevents it from 
exerting its inhibitory function, resulting in enhanced 
movement through the cell cycle (Nanba et al., 2003). 
Interestingly, Bcl6, another transcriptional repressor, 
was also demonstrated to interact with HBEGF-C by a 
similar mechanism. In contrast to PLZF, however, 
binding to HB-EGF-C led to Bcl6 degradation and 
attenuation of its negative regulatory activity (Kinugasa 
et al., 2007; Hirata et al., 2009). 
In light of the dual growth stimulatory effects of 
proHB-EGF cleavage, resulting in liberation of the HB-
EGF ectodomain that can promote autocrine and 
paracrine stimulation of tumor cells, and the HB-EGF-
C carboxyl terminal fragment, that induces cell cycle 
transit, attempts have been made to target both 
biological consequences pharmacologically to achieve 
tumor cell inhibition (Shimura et al., 2008). 
HB-EGF in cancer 
HB-EGF expression is altered in a number of cancer 
types including bladder (Adam et al., 2003; Kramer et 
al., 2007), breast (Ito et al., 2001c; Yotsumoto et al., 
2010), colon (Ito et al., 2001a), hepatic (Inui et al., 
1994), ovarian (Miyamoto et al., 2004; Tanaka et al., 
2005), pancreatic (Kobrin et al., 1994; Ito et al.,2001b) 
and prostate cancers (Freeman et al., 1998) as well as 
gliomas (Mishima et al., 1998). In addition to 
quantitative increases in its expression in tumor versus 
non-tumor tissue, HB-EGF has also been found to 
undergo qualitative changes including altered 
subcellular localization, and cleavage to release N- and 
C-terminal fragments that mediate oncogenic 
behaviors. Notably, although HB-EGF in cancer is 
typically expressed in epithelial cells, we and others 
have reported robust HB-EGF expression in the stroma 
(Freeman et al., 1998; Adam et al., 1999) and 
endothelium (Nolan-Stevaux et al., 2010) in certain 
organs that exerts profound paracrine effects on tumor 
cells. 
To understand the potential functions of HB-EGF in 
cancer, it is instructive to consider the defining 
characteristics of tumor cells In their seminal article 
published 10 years ago Hanahan and Weinberg defined 
six features or 'hallmarks' characteristic of tumor cells 
(Hanahan and Weinberg, 2000). These are: (i) self 
sufficiency in growth signals; (ii) limitless replicative 
potential; (iii) resistance to growth inhibitory signals; 
(iv) evasion of apoptosis; (v) ability to migrate, invade 
and metastasize; and (vi) ability to evoke sustained 
angiogenesis. Recently, it has been argued that the list 
should be updated to include inflammation as an 
additional hallmark of cancer (Colotta et al., 2009). In 
the following sections, we will consider how HB-EGF 
relates functionally these features. 
Self-sufficiency in growth signals and limitless 
replicative potential 
As a ligand for members of the ErbB family of receptor 
tyrosine kinases, it is well established that HB-EGF can 
promote proliferation of a wide range of cells, 
including tumor cells from diverse cancer types. HB-
EGF gene expression is a target of several oncogenes 
including v-jun (Fu et al., 1999), Raf and Ras 
(McCarthy et al., 1995), and can therefore mediate 
growth-promoting effects subsequent to oncogenic 
transformation. 
The growth promoting effects of HB-EGF are mediated 
largely, although not exclusively, through binding to 
ErbB receptors on the plasma membrane. HB-EGF 
binding to EGFR/ErbB1 activates downstream 
signaling that converges on the Raf/Ras/MEK/Erk and
phosphoinositide-3-kinase (PI3K)/Akt pathways to 
promote survival and proliferation (reviewed in Yarden 
and Sliwkowski, 2001). However, recent studies have 
demonstrated receptor-independent activities for HB-
EGF-C, the C-terminal fragment of HB-EGF that 
remains after ectodomain cleavage. In particular HB-
EGF-C has been shown to inhibit the transcription-
repressing capabilities of PLZF and Bcl6 through eit er 
nuclear export or degradation, respectively (Nanba et 
al., 2003; Kinugasa et al., 2007). This resulted in 
enhanced expression of cyclin A and cyclin D2, 
together with increased cell cycle transit. 
Resistance to growth inhibitory signals evasion of 
apoptosis 
HB-EGF has been implicated as a survival factor for 
multiple cell types exposed to growth inhibitory 
stimuli. One of the earliest demonstrations of HB-EGF-
mediated cell survival revealed that whereas proHB-
EGF could prevent TGFβ-induced apoptosis in 
hepatoma cells in culture, this function could not be 
replicated with soluble HB-EGF (Miyoshi et al., 1997). 
That study provided the first demonstration of discrete 
functions for the soluble and cell-associated forms of 
HB-EGF, a concept that has been borne out in many 
subsequent studies both in non-malignant and tumor 
cells (Takemura et al., 1997; Singh et al., 2007; Ray et 
al., 2009). 
It is important to appreciate that HB-EGF expressed by 
cells in the microenvironment has also been implicated 
in tumor cell survival. Circulating cells such as T 
lymphocytes and macrophages that infiltrate tumors 
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have been demonstrated to secrete HB-EGF that can act 
on tumor cells as well as other components critical for 
tumor expansion such as endothelial cells and pericyt s 
(Blotnick et al., 1994; Peoples et al., 1995). The 
cytokine CXCL12 was shown to promote HB-EGF 
release from mononuclear phagocytes and subsequent 
activation of the EGFR/ErbB1 and initiation of pro-
survival signaling in tumor cells (Rigo et al., 2010). 
This in turn stimulated release of the macrophage 
mitogen GM-CSF to further promote HB-EGF in a 
growth stimulatory loop. 
Resistance to growth inhibition and evasion of 
apoptosis are relevant not only to cancer initiation, 
where cells lose responsiveness to normal cell death 
signals, but also in the setting of cancer treatmen 
where tumor cells develop resistance to cytotoxic 
agents. Several recent reports have identified HB-EGF 
as a key mediator of treatment resistance and several 
tumor types. Exposure of cancer cells to either 
conventional chemotherapy or treatment with small 
molecule inhibitors was found to upregulate HB-EGF 
expression, release and activation of the EGFR, thereby 
enhancing survival signaling (Johnson et al., 2005; 
Yotsumoto et al., 2010). Both transcriptional and post-
transcriptional mechanisms have been proposed to 
account for increased HB-EGF levels, including AP-
1/NFkappaB-dependent transcription (Wang et al., 
2007a; Sorensen et al., 2006) and enhanced mRNA 
stability contributing to upregulation of HB-EGF 
protein expression. 
Ability to evoke sustained angiogenesis 
Decades of work by Judah Folkman and colleagues led 
to the concept that tumor growth beyond a defined size
is an angiogenesis-dependent process (reviewed in 
Bishop-Bailey, 2009) i.e. requiring the development of 
a tumor blood supply. Using bladder cancer cells stably 
expressing either soluble or membrane-anchored HB-
EGF, Ongusaha and colleagues demonstrated that HB-
EGF was a potent inducer of several oncogenic 
behaviors including growth and migration in vitro as
well as xenograft growth and angiogenesis in vivo 
(Ongusaha et al., 2004). Consistent with distinct 
functions for soluble and membrane-anchored HBEGF, 
expression of non-cleavable proHB-EGF was unable to 
replicate the tumorigenic potential of either soluble or 
wild type proHB-EGF. The HB-EGF sheddase 
ADAM17 has also been implicated in pathological 
neovascularization. Studies in which ADAM17 was 
deleted conditionally in either endothelial cells or
pericytes using tissue-specific promoters to drive Cr  
recombinase expression demonstrated that loss of 
ADAM17 expression specifically in endothelial cells 
attenuated growth of implanted tumor cells (Weskamp 
et al., 2002). Significantly, effects of ADAM17 
ablation could be restored by administration of 
exogenous HB-EGF, consistent with a role for 
ADAM17-dependent release of HBEGF in regulation 
of angiogenesis. The proangiogenic function of HB-
EGF was verified in an independent study that 
employed the RIP1-Tag2 mouse model of pancreatic 
neuroendocrine tumorigenesis (Nolan-Stevaux et al., 
2010). In that study the authors identified discrete roles 
for HB-EGF expressed by tumor endothelial and 
perivascular cells, and TGFα released by cancer cells 
both of which act through the EGFR to promote 
angiogenesis and tumor cell survival/growth, 
respectively. 
Ability to migrate, invade and metastasize 
To exit the primary tumor and disseminate to distant 
sites in the body, tumor cells must acquire the ability to 
migrate, intravasate, survive in the circulation, 
extravasate and establish in the secondary site. HB-
EGF has been shown to promote prostate cancer cell 
migration and invasion both directly and as an 
intermediate in EGFR transactivation by G-protein 
coupled receptor agonists (Madarame et al., 2003; 
Schäfer et al., 2004a; Cáceres et al., 2008). HBEGF 
was also found to participate in the epithelial-
mesenchymal transition (EMT) in gastric and ovarian 
cancer cells (Yagi et al., 2008). Gastric cancer cells 
exposed to the pathogen Helicobacter pylori, displayed 
increased MMP-7- and gastrin-dependent HB-EGF 
shedding and induction of EMT-associated genes. 
Inhibition of either gastrin or MMP-7 in vitro, or 
gastrin in vivo suppressed expression of HB-EGF and 
EMT-associated genes (Yin et al., 2010). Treatment of 
ovarian cancer cells with recombinant HB-EGF 
reduced E-cadherin levels and upregulated expression 
of Snail, a key regulator of the EMT. Conversely 
RNAi-mediated silencing of Snail attenuated HB-EGF 
expression and release of HB-EGF into the medium. 
Together these findings led the authors to conclude that 
HB-EGF could promote ovarian cancer metastasis 
through induction of the EMT (Yagi et al., 2008). 
Interestingly, Wang and colleagues demonstrated 
opposing effects on E-cadherin expression in pancreti  
cells by retention of HB-EGF on the membrane. In 
cells either expressing non-cleavable proHB-EGF or 
treated with an inhibitor of HB-EGF ectodomain 
shedding, E-cadherin levels were up-regulated as a 
result of inhibition of ZEB1, a transcriptional repr ssor 
for E-cadherin (Wang et al., 2007b). Increased E-
cadherin not only attenuated cell motility, but also 
sensitized cells to chemotherapy-induced apoptosis. 
Regulation of neuroendocrine differentiation and 
inflammation 
Although not strictly defined as 'hallmarks' of caner, 
HB-EGF is known to participate in two additional 
processes linked to development and progression of 
cancer, namely inflammation and neuroendocrine 
differentiation. In intestinal cells exposed to cytokines 
(Mehta and Besner, 2003) or intestinal tissue exposed 
to ischemia/reperfusion injury (Rocourt et al., 2007) 
HB-EGF was found to exert anti-inflammatory activity 
in part through downregulation of NFκB and the 
ensuing reduction in expression of pro-inflammatory 
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cytokines. In contrast, however, HB-EGF expression 
by mesenchymal cells in the liver was upregulated in 
inflamed tissue and augmented by pro-inflammatory 
stimuli (Sagmeister et al., 2008). Moreover, increased 
HB-EGF expression contributed to enhanced DNA 
synthesis and mitogenesis in premalignant hepatocytes 
consistent with a facilitative role for HB-EGF in 
hepatocarcinogenesis. 
In certain cancer types, such as prostate cancer the 
presence of neuroendocrine differentiation is associated 
with more aggressive tumors and worse patient 
outcome (Slovin, 2006). Our group showed that HB-
EGF could drive the neuroendocrine phenotype in 
prostate cancer cells in vitro and in vivo (Kim et al., 
2002; Adam et al., 2002). Notably, cells exposed to 
HB-EGF continued to traverse the cell cycle in contrast 
to previous reports showing inducers of NE 
differentiation promoting cell cycle arrest (Cox et al., 
2000; Wang et al., 2004). Moreover, HB-EGF induced 
downregulation of androgen receptor (AR) expression 
in xenografts as well as AR expression and activity in 
vitro (Adam et al., 2002). Subsequent analysis revealed 
HB-EGF-mediated AR inhibition occurred through an 
mTOR-dependent mechanism involving cap-dependent 
mRNA translation (Cinar et al., 2005). 
HB-EGF as a therapeutic target 
In light of the involvement of HB-EGF in multiple 
aspects of tumor development, progression and 
metastasis, it is not surprising that attempts have be n 
made to target it for therapeutic benefit. Promising 
targeting strategies include prevention of ligand 
binding to the EGFR, inhibition of proHBEGF 
cleavage and subsequent release of ectodomain and C-
terminal fragments and exploitation of proHB-EGF as 
the receptor for diphtheria toxin. In this section, we will 
review the approaches used to inhibit HB-EGF and 
their potential for clinical use. 
In situations where HB-EGF is overexpressed in 
tumors, some of its effects can obviously be blocked in 
the presence of either function blocking anti-EGFR 
antibodies or small molecule inhibitors of the intri sic 
kinase domain. However this topic has been covered in 
many excellent reviews (Laskin and Sandler, 2004; 
Jimeno and Hidalgo, 2005) and will not be considere 
further here. 
A number of studies have exploited the identity of 
proHB-EGF as the receptor for diphtheria toxin (DT) in 
human cells by treating cells, and in some cases 
patients, with a non-toxic DT mutant termed CRM197.  
CRM197 harbors a point mutation (G52E) in the DT A 
chain that diminishes its ability to perform the ADP-
ribosylation of elongation factor 2 and inhibition of
protein synthesis characteristic of wild type DT 
(Mekada and Uchida, 1985). Although CRM197 lacks 
the toxicity of DT, it nonetheless exerts potent growth 
inhibitory effects through binding to the EGF-like 
domain of cell surface and soluble HB-EGF (Mitamura 
et al., 1995; Kageyama et al., 2007). In experimental 
evaluation, CRM197 alone has been found to induce 
apoptosis and inhibit oncogenic behaviors such as 
migration and invasion in vitro and to diminish growth, 
promote apoptosis and suppress angiogenesis in 
xenografts in nude mice (Sanui et al., 2010; Miyamoto 
et al., 2004; Martarelli et al., 2009). In addition, 
enhanced antitumor activity of CRM197 has been 
observed in combination with conventional 
chemotherapeutic agents such as paclitaxel (Yagi et al., 
2009; Sanui et al., 2010). Although the results of 
CRM197 combination chemotherapy are provocative, it 
is important to note that exposure of cells to 
chemotherapeutic agents has been shown to upregulat 
HB-EGF levels that may in turn promote resistance to 
chemotherapy (Wang et al., 2007a). However, by 
careful attention to scheduling of drug administration, 
chemotherapy-induced upregulation of HB-EGF could 
be exploited to sensitize tumor cells to HB-EGF-
targeted agents. 
Based on its demonstrated bioactivity, CRM197 has 
been administered to patients with advanced, treatmnt-
refractory malignant disease (Buzzi et al., 2004). One 
potential limitation of this strategy is that many i  the 
general population are immunized against diphtheria 
and therefore may have innate resistance to CRM197 
delivered systemically. Nevertheless, objective anti-
tumor activity was observed in a small proportion of 
patients, with 3 responses and stable disease in a further 
6 patients. Moreover, CRM197 demonstrated 
reasonable bioavailability, and toxicity associated with 
the treatment was deemed acceptable. Although the 
effect of CRM197 in that study was modest, more 
recent demonstrations of enhanced bioactivity in 
combination with conventional chemotherapeutic 
agents (Yagi et al., 2009; Sanui et al., 2010) suggests 
CRM197 may still have utility as an anti-cancer agent. 
As noted earlier, cleavage of membrane-anchored 
proHB-EGF represents a major control point for 
regulation of HB-EGF bioactivity. Consequently, 
several groups have focused on this event as a means to 
inhibit HB-EGF-dependent regulation of tumor cell 
behavior. Fridman and colleagues described the 
identification of selective inhibitors that could prevent 
shedding of ERBB ligands in vitro and went on to 
demonstrate potent anti-tumor effects in a range of 
assays, including survival pathway activation and 
growth and survival of xenografts (Fridman et al., 
2007). Although such inhibitors are inhibiting shedding 
of multiple EGF-like ligands, in addition to HB-EGF, 
these results suggest the potential for combined 
inhibition of ligand shedding and ERBB receptor 
activation with small molecule inhibitors. In addition to 
preventing release of soluble HB-EGF, 
pharmacological inhibition of MMP/ADAM activity 
using KB-R7785 also suppressed generation and 
nuclear translocation of the HB-EGF C-terminal 
fragment (Shimura et al., 2008). This resulted in 
growth arrest, induction of apoptosis and decreased 
expression of proliferation-associated genes. 
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Summary 
HB-EGF plays multiple important roles in cancer, and 
has been implicated in each of the hallmarks 
characteristic of neoplastic disease. Recent work has 
emphasized the potential for HB-EGF as a viable 
therapeutic target for certain cancer types, through a 
variety of strategies. Moreover, its unique identity 
among ERBB ligands as a receptor for DT/CRM197 
may provide novel avenues for rational targeting in the 
context of cancer therapeutics. The future challenge 
will be to realize this potential and to translate our 
knowledge of this inimitable molecule into treatments 
that benefit humankind. 
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